<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6555">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007110</url>
  </required_header>
  <id_info>
    <org_study_id>11625</org_study_id>
    <nct_id>NCT01007110</nct_id>
  </id_info>
  <brief_title>Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes</brief_title>
  <official_title>The Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DHA, a type of fatty acid, is important in early development, both in terms of reproductive
      physiology of gestation and in postnatal behavioral and cognitive function. In adults, DHA
      has been shown to lower triglycerides and is important to cardiovascular health and
      autonomic control, lowering heart rate and blood pressure and increasing heart variability.
      Little is known about how fatty acids impact cardiac control in infants, children or the
      fetus. Our hypothesis is that maternal DHA supplementation (600 mg/day) will lower fetal HR
      and increase fetal HRV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have observed that maternal DHA supplementation during pregnancy results in lower fetal
      heart rate (HR) and higher heart-rate variability (HRV). In another study, we found that
      infants on DHA supplemented formula have lower HR. Because DHA supplementation in infancy is
      associated with improved neurobehavioral outcomes and infants with lower HR and higher vagal
      control have been found to have improved developmental outcomes, the first aim is to conduct
      a randomized, placebo-controlled trial to determine whether maternal DHA supplementation
      during pregnancy results in lower HR and higher HRV in the fetal period. We will document
      other fetal neurobehaviors (body and breathing movements) as they are hallmarks of fetal
      well-being and influence HR and HRV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>24, 32 and 36 weeks gestational age</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean fetal heart rate calculated from the magnetocardiogram recorded at 24, 32 and 36 weeks gestational age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neonatal Behavioral Assessment Scale (NBAS) Scores</measure>
    <time_frame>within 2 weeks of delivery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The Neonatal Behavioral Assessment Scale (NBAS) measure 6 areas.
For behavioral items a higher score corresponds to more desirable outcomes:
Habituation: Sum of scores across 3 items, scored on a scale of 1-9. Range: 3-27.
Orientation: Sum of scores across 7 items, scored on a scale of 1-9. Range: 7 - 63.
Motor: Sum of scores across 5 items; 3 scored on a scale of 1-9, 1 scored on a scale of 1-6, and 1 scored on a scale of 1-5. Range: 5-38.
Range of State: Sum of scores across 4 items; 2 scored on a scale of 1-6 and 2 scored on a scale of 1-5. Range: 4-22.
Regulation of State: Sum of scores across 4 items, scored on a scale of 1-9. Range: is 4-36.
Autonomic Stability: Sum of scores across 3 items; 1 scored on a scale of 1-9, 1 on a scale of 1-8, and 1 on a scale of 1-6. Range: 3-23.
Reflexes: Sum across the 18 items, scored on a scale of 0-3. Range: 0 to 54. The supplementary items are each scored on a scale of 1-9 and do not combine to form a composite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Red Blood Cell (RBC) Phospholipids at Delivery</measure>
    <time_frame>Time of delivery, 36 weeks to term</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maternal red blood cell phospholipid collected at delivery. These results were compared to baseline red blood cell phospholipid that was collected at study enrollment. A weighed standard fatty acid mixture (Supelco 37 component fatty acid methyl ester mix,Sigma Aldrich) was employed to correct final DHA weight percent of total fatty acids (wt%TFA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cord Blood Phospholipids DHA</measure>
    <time_frame>Birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Newborn red blood cell phospholipids collected at birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Conduction Time</measure>
    <time_frame>Change from Baseline to 2 Months Post-natal</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Docosahexaenoic Acid (DHA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docosahexaenoic Acid (DHA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>soy/corn oil placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA</intervention_name>
    <description>Docosahexaenoic Acid (DHA) from algal oil</description>
    <arm_group_label>Docosahexaenoic Acid (DHA)</arm_group_label>
    <other_name>Docosahexaenoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Algal oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant females 16.0-35.99 years of age who are 12 to 20 weeks gestation at the time
             of enrollment (by dates or ultrasound)

          -  Agree to consume study capsules from enrollment until delivery

          -  BMI &lt;40 at baseline or weight does not exceed 300 pounds

          -  No serious illnesses likely to confound study outcomes

          -  Available by phone

        Exclusion Criteria:

          -  Less than 16 or greater than 35.99 years of age at enrollment

          -  BMI &gt;40 at baseline

          -  Any serious illness likely to confound primary study outcomes

          -  Expecting multiple infants

          -  Diabetes (Type I, II or gestational) at baseline

          -  Elevated blood pressure due to any cause (systolic BP &gt;= 140 mm Hg

          -  Gestational age at baseline &lt; 12 weeks or &gt; 20 weeks

          -  Unable to provide informed consent in English
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Gustafson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gustafson KM, Carlson SE, Colombo J, Yeh HW, Shaddy DJ, Li S, Kerling EH. Effects of docosahexaenoic acid supplementation during pregnancy on fetal heart rate and variability: a randomized clinical trial. Prostaglandins Leukot Essent Fatty Acids. 2013 May;88(5):331-8. doi: 10.1016/j.plefa.2013.01.009. Epub 2013 Feb 20.</citation>
    <PMID>23433688</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>November 2, 2009</firstreceived_date>
  <firstreceived_results_date>February 27, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas</investigator_affiliation>
    <investigator_full_name>Kathleen Gustafson, Ph.D.</investigator_full_name>
    <investigator_title>Research Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>DHA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>soy/corn oil placebo</description>
        </group>
        <group group_id="P2">
          <title>Docosahexaenoic Acid (DHA)</title>
          <description>600 mg Docosahexaenoic Acid (DHA)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Allocation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-Up at 24 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-Up at 32 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-Up at 36 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Neonatal Behavioral Assessment Scale (NB</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>soy/corn oil placebo</description>
        </group>
        <group group_id="B2">
          <title>Docosahexaenoic Acid (DHA)</title>
          <description>600 mg Docosahexaenoic Acid (DHA)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25.6" spread="4.8"/>
                <measurement group_id="B2" value="25.5" spread="4.3"/>
                <measurement group_id="B3" value="25.5" spread="4.51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="67"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Enrollment BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.0" spread="7.0"/>
                <measurement group_id="B2" value="26.8" spread="5.5"/>
                <measurement group_id="B3" value="27.9" spread="6.21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13.9" spread="2.7"/>
                <measurement group_id="B2" value="14.0" spread="3.1"/>
                <measurement group_id="B3" value="14" spread="2.89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gestational Age (GA)</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15.2" spread="3.7"/>
                <measurement group_id="B2" value="13.6" spread="4.1"/>
                <measurement group_id="B3" value="14.4" spread="3.88"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate</title>
        <description>Mean fetal heart rate calculated from the magnetocardiogram recorded at 24, 32 and 36 weeks gestational age.</description>
        <time_frame>24, 32 and 36 weeks gestational age</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Placebo: 19 subjects @ 24 wks GA, 25 subjects @ 32 wks GA, 24 subjects @ 36 wks GA
DHA: 21 subjects @ 24 wks GA, 23 subjects @ 32 wks GA, 22 subjects @ 36 wks GA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>soy/corn oil placebo</description>
          </group>
          <group group_id="O2">
            <title>Docosahexaenoic Acid (DHA)</title>
            <description>600 mg/day docosahexaenoic acid (DHA)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Heart Rate</title>
            <description>Mean fetal heart rate calculated from the magnetocardiogram recorded at 24, 32 and 36 weeks gestational age.</description>
            <units>Beats per minute</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Heart Rate 24 weeks Gestational Age</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="146.0" spread="6.5"/>
                  <measurement group_id="O2" value="145.2" spread="6.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Heart Rate 32 weeks Gestational Age</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="142.5" spread="7.7"/>
                  <measurement group_id="O2" value="140.8" spread="7.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Heart Rate 36 weeks Gestational Age</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="145.0" spread="8.6"/>
                  <measurement group_id="O2" value="141.7" spread="9.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Behavioral Assessment Scale (NBAS) Scores</title>
        <description>The Neonatal Behavioral Assessment Scale (NBAS) measure 6 areas.
For behavioral items a higher score corresponds to more desirable outcomes:
Habituation: Sum of scores across 3 items, scored on a scale of 1-9. Range: 3-27.
Orientation: Sum of scores across 7 items, scored on a scale of 1-9. Range: 7 – 63.
Motor: Sum of scores across 5 items; 3 scored on a scale of 1-9, 1 scored on a scale of 1-6, and 1 scored on a scale of 1-5. Range: 5-38.
Range of State: Sum of scores across 4 items; 2 scored on a scale of 1-6 and 2 scored on a scale of 1-5. Range: 4-22.
Regulation of State: Sum of scores across 4 items, scored on a scale of 1-9. Range: is 4-36.
Autonomic Stability: Sum of scores across 3 items; 1 scored on a scale of 1-9, 1 on a scale of 1-8, and 1 on a scale of 1-6. Range: 3-23.
Reflexes: Sum across the 18 items, scored on a scale of 0-3. Range: 0 to 54. The supplementary items are each scored on a scale of 1-9 and do not combine to form a composite.</description>
        <time_frame>within 2 weeks of delivery</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>soy/corn oil placebo</description>
          </group>
          <group group_id="O2">
            <title>Docosahexaenoic Acid (DHA)</title>
            <description>600 mg/day docosahexaenoic acid</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Neonatal Behavioral Assessment Scale (NBAS) Scores</title>
            <description>The Neonatal Behavioral Assessment Scale (NBAS) measure 6 areas.
For behavioral items a higher score corresponds to more desirable outcomes:
Habituation: Sum of scores across 3 items, scored on a scale of 1-9. Range: 3-27.
Orientation: Sum of scores across 7 items, scored on a scale of 1-9. Range: 7 – 63.
Motor: Sum of scores across 5 items; 3 scored on a scale of 1-9, 1 scored on a scale of 1-6, and 1 scored on a scale of 1-5. Range: 5-38.
Range of State: Sum of scores across 4 items; 2 scored on a scale of 1-6 and 2 scored on a scale of 1-5. Range: 4-22.
Regulation of State: Sum of scores across 4 items, scored on a scale of 1-9. Range: is 4-36.
Autonomic Stability: Sum of scores across 3 items; 1 scored on a scale of 1-9, 1 on a scale of 1-8, and 1 on a scale of 1-6. Range: 3-23.
Reflexes: Sum across the 18 items, scored on a scale of 0-3. Range: 0 to 54. The supplementary items are each scored on a scale of 1-9 and do not combine to form a composite.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Habituation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.92" spread="9.28"/>
                  <measurement group_id="O2" value="8.47" spread="9.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Orienting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.75" spread="15.45"/>
                  <measurement group_id="O2" value="23.40" spread="18.32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Motor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.08" spread="11.40"/>
                  <measurement group_id="O2" value="26.07" spread="18.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>State Organization</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.50" spread="13.89"/>
                  <measurement group_id="O2" value="15.13" spread="8.02"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>State Regulation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.42" spread="20.02"/>
                  <measurement group_id="O2" value="16.93" spread="20.06"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Autonomic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.83" spread="16.90"/>
                  <measurement group_id="O2" value="18.13" spread="14.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reflexes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.92" spread="14.45"/>
                  <measurement group_id="O2" value="22.60" spread="14.33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Red Blood Cell (RBC) Phospholipids at Delivery</title>
        <description>Maternal red blood cell phospholipid collected at delivery. These results were compared to baseline red blood cell phospholipid that was collected at study enrollment. A weighed standard fatty acid mixture (Supelco 37 component fatty acid methyl ester mix,Sigma Aldrich) was employed to correct final DHA weight percent of total fatty acids (wt%TFA).</description>
        <time_frame>Time of delivery, 36 weeks to term</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>soy/corn oil placebo</description>
          </group>
          <group group_id="O2">
            <title>Docosahexaenoic Acid (DHA)</title>
            <description>600 mg/day docosahexaenoic acid</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maternal Red Blood Cell (RBC) Phospholipids at Delivery</title>
            <description>Maternal red blood cell phospholipid collected at delivery. These results were compared to baseline red blood cell phospholipid that was collected at study enrollment. A weighed standard fatty acid mixture (Supelco 37 component fatty acid methyl ester mix,Sigma Aldrich) was employed to correct final DHA weight percent of total fatty acids (wt%TFA).</description>
            <units>weight percent Total Fatty Acids</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.99" lower_limit="4.42" upper_limit="5.69"/>
                  <measurement group_id="O2" value="7.09" lower_limit="5.39" upper_limit="10.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cord Blood Phospholipids DHA</title>
        <description>Newborn red blood cell phospholipids collected at birth.</description>
        <time_frame>Birth</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>soy/corn oil placebo</description>
          </group>
          <group group_id="O2">
            <title>Docosahexaenoic Acid (DHA)</title>
            <description>600 mg/day docosahexaenoic acid</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cord Blood Phospholipids DHA</title>
            <description>Newborn red blood cell phospholipids collected at birth.</description>
            <units>weight percent total fatty acids</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.18" lower_limit="5.81" upper_limit="6.87"/>
                  <measurement group_id="O2" value="7.75" lower_limit="6.01" upper_limit="9.03"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Conduction Time</title>
        <time_frame>Change from Baseline to 2 Months Post-natal</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>soy/corn oil placebo</description>
          </group>
          <group group_id="O2">
            <title>Docosahexaenoic Acid (DHA)</title>
            <description>600 mg/day docosahexaenoic acid</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cardiac Conduction Time</title>
            <units>milliseconds</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38.98" spread="3.62"/>
                  <measurement group_id="O2" value="39.49" spread="2.798"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event Data were reviewed and reported by the Data Safety and Monitoring Board (DSMB) every 6 months for the 2 year duration of the study.</time_frame>
      <desc>Adverse events were categorized by body system affected by the study monitor (systematic assessment). Serious AEs were reported within 24 hours of their occurrence, AEs were reported every 3 months. The DSMB met every 6 months.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>soy/corn oil placebo</description>
        </group>
        <group group_id="E2">
          <title>Docosahexaenoic Acid (DHA)</title>
          <description>600 mg Docosahexaenoic Acid (DHA)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen Gustafson, Ph.D.</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>(913) 588-0065</phone>
      <email>kgustafson@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
